The Weekly Roundup: July 29-August 2

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

We are Biologic Coordinators of Dermatology (BCoD)

Explore how BCs are supported through complex drug approvals and ensuring patients have access to prescribed medications.

Roflumilast Cream 0.15% for Atopic Dermatitis Now Commercially Available

Approved down to the age of 6, the treatment is covered by 2 pharmacy benefit manager contracts to provide timely coverage.

Pediatric Emergency Department Visits with Dystrophic Epidermolysis Bullosa More Frequent in Summer; Hospitalization Rates Exceed 50%

Researchers conducted an assessment of the Nationwide Emergency Department Sample to analyze frequency of visits attributed to young patients with DEB.

Dysmorphic Concern, Body Dysmorphic Disorder More Prevalent in Women with Skin Conditions than Men

Researchers reported gender differences among individuals with skin conditions and compared sociodemographic, clinical, and psychological variables.

Australian Analysis Calls for Diversity in Dermatological Research

Researchers noted how historical bias in dermatology research has impacted the understanding and treatment of conditions in darker skin.

Pediatric Dermatology Highlights in July

From ER visits for dystrophic epidermolysis bullosa to rates of axillary hyperhidrosis, catch up on top pediatric insights from July.

SLIDESHOW: Overview of July 2024 FDA Approvals

Take a deep dive into the 3 approvals for various dermatological conditions this month.

Patients With Acne Vulgaris Exhibit Lower Levels of Serum Zinc, Selenium, and Vitamin D Than General Population

Patients with acne also had higher rates of abnormal zinc and vitamin D levels, especially in severe cases.

Generation Z, Millennials Exhibit Similar Subjective Perception of Atopic Dermatitis Disease Severity

Generation Z patients had lower atopic dermatitis severity but similar disease perception compared to Millennial patients.

Sex and Gender Gaps in Dermatology Treatment

A recent review called for gender-specific studies to enhance dermatological treatments and potentially revise guidelines.

Discovering Dermatology Times: July 2024 Challenging Atopic Dermatitis Cases Supplement

Learn more about the in-depth topics covered in the July 2024 supplement of Dermatology Times.

Interview Intersection: Expert Interviews From July 2024

Dermatology Times is recapping our top expert interviews from the month of July.

BioNTech's mRNA Immunotherapy BNT111 Yields Positive Topline Results in Advanced Melanoma

In combination with cemiplimab, BNT111 contributed to statistically significant and improved overall response rates.

Dermatology Times July 2024 Recap

Dermatology Times is looking back on the top stories in dermatology from the month of July.

Gaps in Post-Inflammatory Hyperpigmentation Research for Skin of Color

PIH, more prominent in darker skin types, often leads to significant psychosocial distress and reduced quality of life.

Patients With Moderate to Severe Alopecia Areata Exhibit Higher Risk of Developing Atopic Dermatitis

Data from a retrospective analysis demonstrated that patients with moderate to severe alopecia areata are at a higher risk of developing atopic dermatitis compared to those with mild alopecia areata.

Discovering Dermatology Times: July 2024 Print

Learn more about the in-depth topics covered in the July 2024 print issue of Dermatology Times.

Dermatology Conferences and Meetings Calendar 2024: August

Dermatology Times asked our readers to share what conferences they are looking forward to in the third quarter of 2024.

Turn Therapeutics Reports Significant IGA and Cytokine Inhibition, Advances to Plans for In-Human Trial

This article represents the first time the news has been shared with the public. Turn's Founder and CEO, Bradley Burnam, shares details.

Dupilumab Shows Promise as Bullous Pemphigoid Treatment

Researchers stated the drug could avoid the need for additional immunosuppressive treatments associated with increased morbidity and mortality.

Restoring Facial Balance and Other Aesthetic Concerns After Weight Loss

Explore solutions for facial volume loss, skin laxity, and in some cases—skin excess.

Insights From the 16th 5CC World Congress

Naiem Issa, MD, PhD, shared highlights from his sessions on the 1726 nm laser for acne, atopic dermatitis disease modification, advances in hidradenitis suppurativa, and microneedling techniques for vitiligo.

Documented Atopic Dermatitis Journeys and Patient Perspectives in Germany

The study focused on the use of Internet resources, number of medical consultations, and factors influencing treatment outcomes.

Study Finds High Relapse Rate After Discontinuing PsO Biologics

Researchers suggested that early intervention with less than 2 years of disease duration was associated with a lower risk of relapse.

Q&A: Biologic Therapies in Pediatric Dermatology - Vaccines, Adverse Effects, and Personalized Care

Michele Ramien, MD, discusses biologic therapies for pediatric dermatology, focusing on their impact on vaccines, managing side effects, and tailoring treatment.

Exploring Safe Alternatives to BPO: Addressing Benzene Risks in Acne Treatments

While FDA action is awaited, dermatology clinicians can suggest BPO-free alternatives such as retinoids, salicylic acid, and more.

Diving Into Deuruxolitinib Data With Natasha Mesinkovska, MD, PhD

The investigator in the clinical development program for deuruxolitinib shared data, patient populations to consider, and more in a recent interview.

Q&A: DaRT Guidelines for Nonmelanoma Skin Cancer Care

Jacob Scott, MD, president and chairman of DaRT, shares highlights of the guidelines and what he hopes clinicians can glean from them.